Effects of Ghrelin Administration on Left Ventricular Function, Exercise Capacity, and Muscle Wasting in Patients With Chronic Heart Failure
Top Cited Papers
- 14 December 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (24) , 3674-3679
- https://doi.org/10.1161/01.cir.0000149746.62908.bb
Abstract
Background— Ghrelin is a novel growth hormone–releasing peptide that also induces vasodilation, inhibits sympathetic nerve activity, and stimulates feeding through growth hormone–independent mechanisms. We investigated the effects of ghrelin on left ventricular (LV) function, exercise capacity, and muscle wasting in patients with chronic heart failure (CHF). Methods and Results— Human synthetic ghrelin (2 μg/kg twice a day) was intravenously administered to 10 patients with CHF for 3 weeks. Echocardiography, cardiopulmonary exercise testing, dual x-ray absorptiometry, and blood sampling were performed before and after ghrelin therapy. A single administration of ghrelin elicited a marked increase in serum GH (25-fold). Three-week administration of ghrelin resulted in a significant decrease in plasma norepinephrine (1132±188 to 655±134 pg/mL; P<0.001). Ghrelin increased LV ejection fraction (27±2% to 31±2%; P<0.05) in association with an increase in LV mass and a decrease in LV end-systolic volume. Treatmen...Keywords
This publication has 22 references indexed in Scilit:
- Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKTThe Journal of cell biology, 2002
- Hemodynamic, Renal, and Hormonal Effects of Ghrelin Infusion in Patients with Chronic Heart FailureJournal of Clinical Endocrinology & Metabolism, 2001
- Short-term Oral Administration of l-Arginine Improves Hemodynamics and Exercise Capacity in Patients with Precapillary Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Ghrelin Strongly Stimulates Growth Hormone Release in HumansJournal of Clinical Endocrinology & Metabolism, 2000
- Growth Hormone-Independent Cardioprotective Effects of Hexarelin in the Rat1Endocrinology, 1999
- Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathyThe Lancet, 1998
- Wasting as independent risk factor for mortality in chronic heart failurePublished by Elsevier ,1997
- A Preliminary Study of Growth Hormone in the Treatment of Dilated CardiomyopathyNew England Journal of Medicine, 1996
- Idiopathic Dilated CardiomyopathyNew England Journal of Medicine, 1994
- The Pathogenesis of Cardiac CachexiaNew England Journal of Medicine, 1964